TD Asset Management Inc Takes $1.34 Million Position in Enliven Therapeutics, Inc. $ELVN

Key Points

• TD Asset Management Inc has acquired a new stake in Enliven Therapeutics, Inc., purchasing 66,906 shares valued at approximately $1.34 million.
• Analysts have differing views on the stock, with HC Wainwright raising their price target from $40.00 to $48.00 while Weiss Ratings issued a "sell" rating; the current consensus rating is "Moderate Buy" with an average price target of $41.20.
• Insiders have sold 103,234 shares of Enliven Therapeutics in the last 90 days, with notable transactions by COO Anish Patel and insider Joseph P. Lyssikatos.

TD Asset Management Inc bought a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 66,906 shares of the company's stock, valued at approximately $1,342,000. TD Asset Management Inc owned approximately 0.14% of Enliven Therapeutics as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the business. GAMMA Investing LLC lifted its holdings in shares of Enliven Therapeutics by 3,058.1% during the 1st quarter. GAMMA Investing LLC now owns 2,716 shares of the company's stock valued at $53,000 after purchasing an additional 2,630 shares during the last quarter. Quantbot Technologies LP acquired a new position in Enliven Therapeutics during the 1st quarter valued at about $60,000. KLP Kapitalforvaltning AS increased its position in Enliven Therapeutics by 58.1% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company's stock valued at $136,000 after buying an additional 2,500 shares in the last quarter. BIT Capital GmbH purchased a new stake in Enliven Therapeutics in the first quarter valued at about $382,000. Finally, Invesco Ltd. boosted its holdings in Enliven Therapeutics by 39.6% in the first quarter. Invesco Ltd. now owns 21,044 shares of the company's stock worth $414,000 after acquiring an additional 5,972 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. HC Wainwright upped their price objective on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a report on Wednesday, July 2nd. Weiss Ratings reissued a "sell (d-)" rating on shares of Enliven Therapeutics in a research report on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Enliven Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $41.20.

Insider Buying and Selling

In related news, insider Joseph P. Lyssikatos sold 12,500 shares of the firm's stock in a transaction on Monday, October 20th. The stock was sold at an average price of $22.08, for a total value of $276,000.00. Following the completion of the transaction, the insider owned 915,188 shares in the company, valued at $20,207,351.04. This trade represents a 1.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Anish Patel sold 6,667 shares of the firm's stock in a transaction on Monday, September 8th. The stock was sold at an average price of $20.24, for a total value of $134,940.08. Following the completion of the transaction, the chief operating officer owned 283,308 shares of the company's stock, valued at $5,734,153.92. This trade represents a 2.30% decrease in their position. The disclosure for this sale can be found here. Insiders sold 103,234 shares of company stock worth $2,093,844 in the last 90 days. Insiders own 25.90% of the company's stock.

Enliven Therapeutics Price Performance

Shares of ELVN stock opened at $20.49 on Thursday. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -10.25 and a beta of 0.85. The business has a fifty day moving average of $20.13 and a 200 day moving average of $19.63. Enliven Therapeutics, Inc. has a 1 year low of $13.30 and a 1 year high of $29.78.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its earnings results on Wednesday, August 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04. As a group, equities research analysts expect that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

Want to see what other hedge funds are holding ELVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.